Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bearish -25

Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

AI-generated analysis

📉 Abbott (ABT) shares closed at $85.68, dropping 1.14% while the broader S&P 500 and major indices posted gains.

⬇️ The stock has been under pressure recently, falling 7.66% prior to today despite a medical sector rise of 2.02%.

📅 Analysts project Abbott will report earnings per share of $1.28 in the upcoming quarter, representing 1.59% year-over-year growth.

💰 Consensus revenue estimates stand at $12.53 billion for the next quarter, reflecting a 12.43% increase from last year's equivalent period.

📈 For the full year, forecasts estimate earnings of $5.48 per share and revenue of $50.49 billion, with projected growth of 6.41% and 13.9% respectively.

⚖️ Abbott currently trades at a Forward P/E ratio of 15.82, which is below the industry average of 18.69.

🤝 The company's PEG ratio is 1.45, slightly lower than the industry average of 1.5.

🏆 Zacks Consensus EPS estimates have shifted 0.42% lower over the last 30 days, impacting the proprietary Zacks Rank model.

⚠️ Abbott currently holds a Zacks Rank of #4 (Sell), while its Medical - Products industry ranks in the bottom 35% of over 250 industries.

📊 Top-rated industries historically outperform bottom half groups by a factor of 2 to 1 according to research data.

🔍 Investors are encouraged to monitor analyst estimate revisions as they correlate with near-term stock price movements.

Bullish Signals
  • Abbott is expected to post EPS of $1.28 with 1.59% growth compared to the equivalent quarter last year, indicating steady earnings expansion.
  • Consensus revenue estimate is projected at $12.53 billion, reflecting a 12.43% rise from the equivalent quarter last year.
  • Full-year consensus forecasts earnings of $5.48 per share with +6.41% growth and revenue of $50.49 billion indicating +13.9% compared to the previous year.
  • Abbott's Forward P/E ratio of 15.82 is trading at a discount compared to its industry average Forward P/E of 18.69, suggesting potential valuation upside.
  • The company's PEG ratio of 1.45 is lower than the industry average of 1.5, signaling the stock may be undervalued relative to its earnings growth prospects.
Risk Factors
  • Abbott stock fell -1.14% while the broader S&P 500 gained 0.02%, Dow added 0.36%, and Nasdaq gained 0.07%, indicating underperformance relative to major indices.
  • Shares lost 7.66% prior to trading, significantly lagging the Medical sector's gain of 2.02% and the S&P 500's substantial gain of 5.12%.
  • The company currently holds a Zacks Rank of #4 (Sell), which is a bearish rating within a system ranging from #1 (Strong Buy) to #5 (Strong Sell).
  • The Medical - Products industry is ranked 160th out of 250+ industries, placing it in the bottom 35% and trailing the top 50% of rated industries by a factor of 2 to 1 in terms of expected outperformance.
Full Analysis
Abbott Laboratories stock dropped 1.14% to $85.68 at the close, trailing both the broader S&P 500 and medical sector despite an overall market uptick that added value to major indices. The company had already lost nearly 7.7% in the session preceding this report, outperforming only when compared to its underperformance relative to its sector peers. Analysts are eyeing Abbott's upcoming earnings report with specific projections for earnings per share at $1.28 and revenue of $12.53 billion for the quarter, figures that represent single-digit EPS growth and double-digit revenue expansion based on current consensus estimates. Looking further out at annual forecasts, analysts expect Abbott to generate $5.48 in earnings and $50.49 billion in revenue for the full year, both metrics up roughly 6% to 14% respectively from the prior year. In terms of valuation metrics, Abbott currently trades at a forward price-to-earnings ratio of 15.82 compared to an industry average of 18.69, indicating a slight discount relative to peers. The company also maintains a PEG ratio of 1.45 against an industry average of 1.50, suggesting its valuation is commensurate with expected earnings growth. The stock currently holds a Zacks Rank of #4, which the research firm categorizes as a Sell rating based on their proprietary model that combines estimate revisions with near-term price predictions. Over the last month, the consensus EPS estimate for Abbott has drifted down by 0.42%. While the Medical Products industry ranks within the bottom 35% of all industries tracked by the system, historical data suggests that top-rated sectors outperform weaker ones by a factor of two to one, highlighting potential risks associated with the company's current positioning relative to its broader peer group and sector performance.